云南高校图书馆联盟文献共享服务平台- ANTI-EGFR

ANTI-EGFR: 作品数：32被引量：79H指数：5; 导出分析报告; 相关作者：丛林海张贵祥解学乾唐纳王悍更多>>; 相关机构：南京医科大学上海市第一人民医院山东大学昆明医学院第一附属医院更多>>; 相关期刊：《中国癌症杂志》《Cancer Communications》《Chinese Medical Sciences Journal》《Chinese Journal of Cancer Research》更多>>; 相关基金：国家自然科学基金广东省自然科学基金浙江省公益性技术应用研究计划项目浙江省医药卫生科学研究基金更多>>

HLX07 alone or combined with serplulimab,cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma:A phase 2 study: 《Cancer Communications》2024年第12期1431-1443,共13页Yun Liu Yanfeng Wang Yanrong Zhu Tao Wu Zhenyang Liu Jin Zhou Yuan Yuan Mudan Yang Bo Liu Zhenbo Tan Wu Zhuang Jiayan Chen Ning Li Ying Wang Xuhui Hu Lin Wang Haoyu Yu QingyuWang Jun Zhu Jing Huang; Shanghai Henlius Biotech Inc.; Background:The combination of anti-PD-1 antibody serplulimab and chemotherapy is considered standard first-line therapy for advanced esophageal squamous cell carcinoma(ESCC),but few later-line treatments are available...; 关键词：ANTI-EGFR esophageal squamous cell carcinoma HLX07 phase 2 serplulimab

融合蛋白anti-EGFR-iRGD修饰的红细胞外囊泡联合siRNA靶向抑制三阴性乳腺癌恶性进程: 《现代肿瘤医学》2024年第17期3197-3205,共9页韦雪妮杨忠慧黄吉陈国梅成昌娟; 江苏省苏州市科技发展计划(民生科技-医疗卫生应用基础研究)项目(编号:SYSD2020172)。; 目的:通过红细胞来源的细胞外囊泡(red blood cell-derived extracellular vesicles,RBCEVs)构建靶向递送系统以提高对三阴性乳腺癌(triple-negative breast cancer,TNBC)恶性进程的抑制效率。方法:采用脂质插入法将融合蛋白anti-抗人...; 关键词：红细胞来源的细胞外囊泡三阴性乳腺癌 SIRNA 上皮间充质转化脂质插入法连环蛋白β1

Phase Ib study of anti-EGFR antibody(SCT200)in combination with anti-PD-1 antibody(SCT-I10A)for patients with RAS/BRAF wild-type metastatic colorectal cancer: 《Cancer Biology & Medicine》2024年第7期636-650,共15页Ming Bai Yao Lu Chunmei Shi Jianwei Yang Wei Li Xianli Yin Chenghui Huang Lin Shen Liangzhi Xie Yi Ba; funded by Tianjin Key Medical Discipline(Specialty)Construction Project(Grant No.TJYXZDXK-009A);National Natural Science Foundation of China(Grant No.82103677);National Science and Technology Major Projects of China(Grant No.2019ZX09732-001)。; Objective:This study evaluated the safety and efficacy of an anti-epidermal growth factor receptor(EGFR)antibody(SCT200)and an anti-programmed cell death 1(PD-1)antibody(SCT-I10A)as third-line or subsequent therapies ...; 关键词：Colorectal cancer SCT-I10A SCT200 epidermal growth factor receptor programmed cell death 1

Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report: 《World Journal of Gastrointestinal Oncology》2024年第2期557-562,共6页Toshiaki Tsurui Yuya Hirasawa Yutaro Kubota Kiyoshi Yoshimura Takuya Tsunoda; BACKGROUND Hyperbilirubinemia with hepatic metastases is a common complication and a poor prognostic factor for colorectal cancer(CRC).Effective drainage is often im-possible before initiating systemic chemotherapy,ow...; 关键词：Colorectal neoplasms PANITUMUMAB Chemotherapy HYPERBILIRUBINEMIA JAUNDICE Case report

anti-EGFR scFv-FTH1/AP1-FTH1纳米粒子的构建及其治疗哮喘小鼠的应用: 《华东理工大学学报（自然科学版）》2023年第5期693-701,共9页汪蓉蓉张天宝曹旭妮; 国家自然科学基金(21375039);上海市科委科技创新行动计划资助项目(19142201300)。; 采用基因工程方法分别将抗表皮生长因子受体(EGFR)的单链抗体(anti-EGFR scFv)和靶向白介素-4-受体(IL-4R)的AP1短肽分别修饰到铁蛋白重链亚基(FTH1)的N端,再通过蛋白表达、体外混合复性后成功制备了anti-EGFR scFv-FTH1/AP1-FTH1双靶...; 关键词：哮喘铁蛋白纳米粒子表皮生长因子受体白介素-4受体

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma被引量：4: 《Cancer Biology & Medicine》2022年第3期358-369,共12页Ming Bai Meng Wang Ting Deng Yuxian Bai Kai Zang Zhanhui Miao Wenlin Gai Liangzhi Xie Yi Ba; supported by a grant from the Science&Technology Development Fund of the Tianjin Education Commission for Higher Education(Grant No.2018KJ046).; Objective:The mainstay treatment of esophageal squamous cell carcinoma(ESCC)involves chemotherapy and immunotherapy.However,alternative therapies are required for patients who are refractory or intolerant to existing ...; 关键词：Epidermal growth factor receptor esophageal squamous cell carcinoma SCT200 monoclonal antibody

Anti-EGFR therapy in metastatic colorectal cancer:mechanisms and potential regimens of drug resistance被引量：14: 《Gastroenterology Report》2020年第3期179-191,I0001,共14页Qing-Hai Li Ying-Zhao Wang Jian Tu Chu-Wei Liu Yu-Jie Yuan Run Lin Wei-Ling He Shi-Rong Cai Yu-Long He Jin-Ning Ye; supported by the National Natural Science Foundation of China[81871994 and 81701834];the Guangdong Natural Science Foundation[2019B151502063];the Guangdong Science and Technology Planning Program[20190202018].; Cetuximab and panitumumab,as the highly effective antibodies targeting epidermal growth factor receptor(EGFR),have clinical activity in the patients with metastatic colorectal cancer(mCRC).These agents have good curat...; 关键词：metastatic colorectal cancer EGFR drug resistance CETUXIMAB PANITUMUMAB

Re-treatment Using Cetuximab and Chemotherapy in Patients with Metastatic Colorectal Cancer Harboring Wild-type RAS Gene: 《Advances in Modern Oncology Research》2018年第6期18-21,共4页Kakil Ibrahim Rasul Mohamed U Al-Homsi; Colorectal cancer is a heterogeneous disease.Activating mutations in genes like K-RAS,BRAF,and PI3K contribute towards a poor prognosis of the disease.In this report,we present the case of re-treatment of a 58-year ol...; 关键词：Metastatic colorectal cancer ANTI-EGFR antibodies CETUXIMAB K-RAS CHEMOTHERAPY

制备anti-EGFR-PEG-SPIO靶向纳米分子探针对肺腺癌细胞行体外靶向MR成像被引量：4: 《中国医学影像技术》2017年第12期1797-1801,共5页王中领唐纳王悍解学乾张在先张贵祥; 国家自然科学基金(81371623); 目的探讨anti-EGFR-PEG-SPIO纳米分子探针对表皮生长因子受体(EGFR)高表达肺腺癌细胞的靶向性及利用MRI对其监测的可行性。方法制备anti-EGFR靶向纳米分子探针(anti-EGFR-PEG-SPIO)及非靶向纳米分子探针(PEG-SPIO),行电镜(TEM)观察,并...; 关键词：靶向成像肺腺癌分子探针超顺磁性氧化铁

靶向制剂＾131I-Anti-EGFRvⅢ的制备及其在恶性胶质瘤裸鼠中的显像分布被引量：1: 《中华神经医学杂志》2016年第9期878-883,共6页安雷魏大年黄凯张冠华朱永晖刘铁坚刘承勇; 广东省自然科学基金（S2011010005324）; 目的探讨放射性核素碘131（^131I）标记表皮生长因子受体Ⅲ型突变体抗体（Anti-EGFRvⅢ）的实验方法、条件以及标记产物^131I-Anti-EGFRvⅢ在恶性胶质瘤裸鼠体内的靶向性分布。方法采用Iodogen法进行Anti-EGFRvⅢ的^131I标记，SephadexG...; 关键词：神经胶质瘤碘131 表皮生长因子受体Ⅲ型突变体抗体放射性核素显像

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

ANTI-EGFR

检索结果分析

下载全文

高级检索检索式检索

时间限定

期刊范围

学科限定全选

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

ANTI-EGFR

检索结果分析

下载全文

用户登录

高级检索检索式检索